Claims for Patent: 10,179,120

Summary for Patent: 10,179,120

Title:	Dosage regimen of ferric trimaltol
Abstract:	The present invention relates to a dosage regimen of ST10 (ferric trimaltol) for the treatment of patients suffering from iron deficiency with or without anaemia. Specifically the invention relates to the treatment of patients with 30 mg ST10 twice daily.
Inventor(s):	Schweiger; Christian (Wollerau, CH), Sterritt; Carl Andrew (Wollerau, CH), Howell; Julian David (Wollerau, CH)
Assignee:	Iron Therapeutics Holdings AG (Wollerau, CH)
Application Number:	15/110,003
Patent Claims:	1. A method for the treatment of iron deficiency with or without anaemia in a patient, comprising administering orally to the patient ferric trimaltol as a 30 mg elemental iron preparation on an empty stomach twice daily, wherein the percentage of ferric trimaltol is at least 60% of the combined weight of ferric trimaltol and excipients, wherein iron deficiency with or without anaemia is a result of, or associated with active inflammatory disease or active acute/chronic inflammation. 2. The method of claim 1 wherein iron deficiency is iron deficiency with anaemia in inflammatory bowel disease. 3. The method of claim 2 wherein the inflammatory bowel disease is Crohn's disease. 4. The method of claim 2 wherein the inflammatory bowel disease is ulcerative colitis. 5. The method of claim 1 wherein said ferric trimaltol 30 mg elemental iron preparation is administered once prior to breakfast and once prior to sleep. 6. The method of claim 1 wherein the ferric trimaltol 30 mg elemental iron preparation is administered for up to a twelve week period. 7. The method of claim 6, further comprising administering orally after the twelve week period to the patient ferric trimaltol as a 30 mg-120 mg elemental iron preparation once daily, or once every two, three, four, five, six or seven days. 8. The method of claim 1 wherein the ferric trimaltol 30 mg elemental iron preparation is administered indefinitely as a maintenance dose. 9. The method of claim 1 wherein the ferric trimaltol 30 mg elemental iron preparation is a size 1 capsule. 10. The method of claim 1 wherein the ferric trimaltol 30 mg elemental iron preparation comprises: 231.5 mg ferric trimaltol, 91.5 mg lactose monohydrate, 3.0 mg sodium lauryl sulphate, 9.0 mg crospovidone, 0.6 mg colloidal silicon dioxide, and 3.0 mg magnesium stearate. 11. A method for the treatment of iron deficiency with or without anaemia in a patient, comprising administering orally to the patient ferric trimaltol as a 30 mg elemental iron size 1 capsule on an empty stomach twice daily, once prior to breakfast and once prior to sleep for up to a twelve week period, wherein the percentage of ferric trimaltol is at least 60% of the combined weight of ferric trimaltol and excipients, wherein iron deficiency with or without anaemia is a result of, or associated with active inflammatory disease or active acute/chronic inflammation.